However, as part of the tumor immune microenvironment, the intratumoral microbiome of lung cancer, which is the leading tumor ...

A phase 1b trial is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell ...

preclinical advances and ongoing clinical evaluation in intratumoral Immunotherapy PH-762, an INTASYL siRNA compound targeting PD-1, is being evaluated in an ongoing clinical trial (NCT 06014086) as a ...

The following is a summary of "Multiscale deep learning radiomics for predicting recurrence-free survival in pancreatic ...

Privo Technologies, a phase 3 clinical-stage biopharmaceutical company specializing in drug delivery and cancer treatment in ...

PH-762 is currently being evaluated in a U.S. multi-center Phase 1b dose-escalating clinical trial through the intratumoral injection of PH-762 for the treatment of patients with cutaneous ...

Silexion's new expanded dual-route strategy will integrate intratumoral and systemic administration to target both primary tumors and metastases, supported by strong preclinical data from SIL204 and ...